CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Mana.bio›
Library
Mana.bio

Mana.bio

Mana.bio: An AI-driven startup specializing in LNP development for mRNA-based therapies and vaccines.

Operating headquarters
Tel Aviv, Tel Aviv District, IL🇮🇱
Founded
2021
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Library

Mana.bio - Library

mana.bio·Crawled Oct 1, 2026·

Topics

Publication type

Content origin
Row density

Blog

1 page
  1. LAB to STARTUP podcast - Designing the Future of Drug Delivery: How AI is Solving RNA's Biggest Challenge/news/lab-to-startup-podcast:-

    Host Naresh Sunkara speaks with our CEO Yogev Debbi and scientific co-founder Avi Schroeder about how automation and AI are converging to transform nucleic acid therapeutic development, enabling faster and more predictable design of RNA- and DNA-based medicines

Press

5 pages
  1. A Call to Lead Podcast/news/a-call-to-lead

    Interview highlighting the strong co-founder relationship that led to the formation of Mana.bio.

  2. Mana.bio Announces Strategic Leadership Additions and Upcoming Presentation at ASGCT 2026 Annual Meeting/news/entree-advisors-asgct2026

    Mana.bio announces the addition of three accomplished industry leaders to our board of directors and strategic advisors alongside an upcoming poster presentation at the American Society of Gene & Cell Therapy 2026 Annual Meeting. These advisors bring deep expertise in mRNA therapeutics, LNP delivery, business development, and strategic partnerships to support the company's next phase of growth. This exciting progress is illustrated in Mana.bio's ASGCT poster, which highlights the company's progr

  3. Mana.bio Presents New Data Demonstrating the Power of AI Towards Unlocking the Potential of RNA Medicine/news/mana.bio-presents-new-data-demonstrating-the-power-of-ai-towards-unlocking-the-potential-of-rna-medicine

    Mana.bio is excited to announce the presentation of three new posters at the upcoming American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting, taking place from May 13–17 in New Orleans, LA

  4. News/news

    Dr. Sepp Lorenzino is a true pioneer in genetic medicine. Having overseen some of the most significant breakthroughs in the industry during her time as CSO of Intellia Therapeutics, Inc., and in leadership roles at Vertex Pharmaceuticals, Alnylam Pharmaceuticals, and Merck, she knows exactly what it takes to move complex modalities from early research through clinical development.

Careers & Hiring

1 page
  1. Jobs/jobs

Homepage

2 pages
  1. Homepage/

    Mana.bio is an AI-based drug delivery startup specializing in programmable drug delivery and gene therapy, with a focus on lipid nanoparticles (LNPs), RNA-based therapeutics, DNA therapeutics, and vaccines.

  2. Homepage/

    Mana.bio is an AI-based drug delivery startup specializing in programmable drug delivery and gene therapy, with a focus on lipid nanoparticles (LNPs), RNA-based therapeutics, DNA therapeutics, and vaccines.

Coverage

5 items
  1. Mana.bio Announces Strategic Leadership Additions and Upcoming Presentation at ASGCT 2026 Annual Meetingprnewswire.com/news-releases/manabio-announces-strategic-leadership-additions-and-upcoming-presentation-at-asgct-2026-annual-meeting-302761772.html

    Mana.bio adds three leadership figures and plans to present machine learning-driven lipid nanoparticle (LNP) data for in vivo T-cell engineering at the ASGCT 2026 Annual Meeting. Thaminda Ramanayake joins its board, Michelle Lynn Hall becomes a board observer, and Guy Van Meter joins as strategic advisor.

    May 2026 · PR NewswireNews article

  2. Mana.bio Unveils Mina, the World’s First LLM-Powered AI Agent for Lipid Nanoparticlesmana.bio/news/mana.bio-unveils-mina%E2%84%A2%2C-the-world%E2%80%99s-first-llm-powered-ai-agent-for-lipid-nanoparticles

    Mana.bio launches Mina, an LLM-based AI agent built specifically for lipid nanoparticles. The company describes Mina as the world’s first LLM-powered agent for this field. It provides curated data, predictive modeling, and formulation insights intended to accelerate LNP discovery and RNA-based medicines.

    Sep 2025 · Mana.bioNews article

  3. Israeli biotech startup mana.bio launches AI-fueled programmable drug therapy

    Israeli biotech startup Mana.bio launches a programmable drug treatment solution that uses an AI-driven approach involving liquid nanoparticles (LNP). The company had planned the launch for months and proceeds despite attacks in Israel over the preceding weekend.

    Oct 2023 · TechCrunchNews article

  4. Israeli biotech startup Mana.bio launches AI-fueled programmable drug therapy

    Israeli biotech startup Mana.bio launches an AI-fueled programmable drug treatment solution, using AI to design lipid nanoparticles (LNPs) intended to enable programmable drug treatments. The company says it has planned the launch for months and moves ahead despite attacks in Israel the previous weekend.

    Oct 2023 · TechCrunchNews article